Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-Pd-L1 Antibody, for Advanced Urothelial Carcinoma
27 avr. 2021 11h39 HE
|
Sorrento Therapeutics, Inc.
STI-3031 was discovered from Sorrento’s fully human G-MAB™ library.Currently, six G-MAB antibodies are in Phase 1b through Phase 3 clinical trials in immuno-oncology and COVID-19 indications.These...
Sorrento Announces Positive Results of Phase 1b Study of COVI-MSC™ Treatment of ICU Covid-19 Patients, Achieving 100% (10 out 10) Discharge Rate
20 avr. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
The target enrollment of 10 patients with acute respiratory failure due to COVID-19 has been accomplished.All 10 patients were discharged from hospital within three days after their last COVI-MSC...
Sorrento Enters Into Merger Agreement to Acquire Late-Stage Oncology Company ACEA Therapeutics
05 avr. 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell...
Sorrento Announces Updated Positive Results of Phase 1b Study of COVI-MSC™ for Treatment of ICU COVID-19 Patients
25 mars 2021 15h58 HE
|
Sorrento Therapeutics, Inc.
All nine patients with acute respiratory failure due to COVID-19 discharged from hospital within days after 3rd COVI-MSC infusionPreparations are ongoing for initiating Phase 2 placebo-controlled...
Sorrento Announces First Patient Treated in Phase IB AL Amyloidosis Trial with STI-6129, an Anti-CD38 Antibody-Drug Conjugate
18 mars 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
STI-6129 is an antibody-drug conjugate (ADC) composed of a fully human monoclonal anti-CD38 antibody covalently bound by a proprietary chemical linker to a duostatin tubulin inhibitor.Amyloid Light...
Sorrento and Mount Sinai Health System Enter Into Exclusive License Agreement for Development of Potent Antibody Combinations Aimed at Neutralizing SARS-CoV-2 and the Emerging United Kingdom and South Africa Variants of COVID-19
09 mars 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Sorrento is moving forward with the research and development of COVISHIELD antibody combinations with potentially potent neutralizing activities against early COVID-19 pandemic virus isolates as well...
Lee’s Pharmaceutical Announces its Anti-PD-L1 Antibody Socazolimab, Licensed From Sorrento Therapeutics, Receives Clearance to Start Phase 3 Trial as a First-line Treatment of Extensive-stage Small-Cell Lung Cancer
07 mars 2021 22h27 HE
|
Sorrento Therapeutics, Inc.
Socazolimab is an anti-PD-L1 antibody licensed from Sorrento for the Greater China Territory by Lee’s Pharm.China’s National Medical Products Administration (“NMPA”) clears Lee’s Pharm to conduct a...
Dr. Henry Ji to Participate in the H.C. Wainwright Virtual GLOBAL LIFE SCIENCES CONFERENCE 2021 Investor Conference
05 mars 2021 01h06 HE
|
Sorrento Therapeutics, Inc.
SAN DIEGO, March 04, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"), announced today that Dr. Henry Ji, Chairman and CEO, will participate in the following upcoming...
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Study for STI-2099 (Intranasal COVIDROPS) in Healthy Volunteers and Outpatient Treatment for Newly Diagnosed COVID-19 Positive Patients
02 mars 2021 16h02 HE
|
Sorrento Therapeutics, Inc.
FDA granted IND clearance today for the commencement of a Phase 1 safety and pharmacokinetic study for STI-2099 (COVIDROPS™) in healthy volunteers and outpatients with mild COVID-19 disease with or...
Sorrento Receives FDA Clearance to Start Clinical Trial of Anti-CD47 Antibody, Discovered from Fully Human G-MAB Library, for Treatment of Multiple Malignancies
02 mars 2021 09h00 HE
|
Sorrento Therapeutics, Inc.
Internally developed fully human anti-CD47 antibody (STI-6643) cleared for basket trial;No complicated titration or priming dose of the antibody is required to reduce toxicity;This study will be...